natgillin/translations-raw huggingface dataset:
an enteric coating. The composition of claim 7, wherein the alkalizing agent is an alkali or earth alkali hydroxide, an alkali or earth alkali carbonate, an alkali or earth alkali hydrogen carbonate, a phosphate, a glucosamine or a mixture of two or more of these compounds, preferably sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, sodium phosphate or a mixture of two or more of these components, more preferably sodium carbonate. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da sredstvo za alkalizaciju je alkalijski ili zemnoalkalijski hidroksid, alkalijski ili zemnoalkalijski karbonat, alkalijski ili zemnoalkalijski hidrogenkarbonat, fosfat, glukozamin ili mješavina od dva ili više tih spojeva, poželjno je to natrijev hidroksid, natrijev karbonat, natrijev hidrogenkarbonat, natrijev fosfat ili mješavina od dva ili više tih sastojaka, a najpoželjniji je natrijev karbonat.
This was determined by calculation of the concentration of compound that was required to give 50% inhibition of phosphorylation in this assay. 
Ona je određena računanjem koncentracije spoja koja je potrebna za 50%-tnu inhibiciju fosforilacije u ovom testu.
"substituted alkyl" refers to an alkyl group substituted by, one to four substituents, selected from halo, hydroxy, alkoxy, oxo, alkanol aryloxy, alkanoyloxy, amino, alkylamino, arylamino, aralkylamino, disubstituted amines in which the 2 amino substituents are selected from alkyl, aryl or aralkyl; alkanoylamino, aroylamino, aralkanoylamino, substituted alkanoylamino, substituted arylamino, substituted aralkanoylamino, thiol, alkylthio, arylthio, aralkylthio, alkylthiono, arylthiono, aralkylthiono, alkylsulfonyl, arylsulfonyl, aralkysulfonyl, sulfonamido, substituted sulfonamido, nitro, cyano, carboxy, carbamyl, substituted carbamyl alkoxycarbonyl, aryl, substituted aryl guanidino, heterocyclyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, homopiperazinyl, and substituted heterocyclyl, wherein in cases where the substituent is further substituted it will be selected from alkyl, alkoxy, aryl or aralkyl. 
"supstituirani alkil" označava alkil skupinu supstituiranu sa, jednim do četiri supstituenta, izabranih iz skupine koju čine halo, hidroksi, alkoksi, okso, alkanol ariloksi, alkanoiloksi, amino, alkilamino, arilamino, aralkilamino, disupstituirani amini u kojima su 2 amino supstituenta izabrana od alkil, aril ili aralkil; alkanoilamino, aroilamino, aralkanoilamino, supstituirani alkanoilamino, supstituirani arilamino, supstituirani aralkanoilamino, tiol, alkiltio, ariltio, aralkiltio, alkiltiono, ariltiono, aralkiltiono, alkilsulfonil, arilsulfonil, aralkilsulfonil, sulfonamido, supstituirani sulfonamido, nitro, cijano, karboksi, karbamil, supstituirani karbamil alkoksikarbonil, aril, supstituirani aril guanidino, heterociklil, imidazolil, furil, tienil, tiazolil, pirolidil, piridil, pirimidil, pirolidinil, piperidinil, morfolinil, piperazinil, homopiperazinil, i supstituirani heterociklil, pri čemu, u slučajevima gdje je supstituent dalje supstituiran on će biti izabran od alkil, alkoksi, aril ili aralkil.
The composition-of-matter of claim 17, wherein said carbohydrate is selected from the group consisting of agarose, sepharose, and cellulose. 
Predmetni pripravak prema zahtjevu 17, naznačen time da je navedeni ugljikohidrat odabran iz skupine koja seo sastoji od agaroze, sefaroze i celuloze.
• effective agitation of egg, sweetener and fat for 3 minutes, 
energično miješanje jaja, sladila i masti 3 minute, .
Figure 4 shows numerous alternative groups that may be used for the R7COO group at the 10-a-position of generalized formula G . As would be appreciated by the ordinarily skilled person, these acylations may be performed for example by substituting the appropriate carboxylic acid R7COOH, carboxylic acid halide R7COX or carboxyl anhydride R7COOCOR7 in the above procedures. As indicated above and as further illustrated in Scheme 3, taxanes of generalized formula F or G may be deprotected at the 2'- and 7-positions in either a two-step process or a single step. 
Slika 4 prikazuje brojne alternativne skupine koje se mogu koristiti za R;COO skupinu kod 10-a-položaja opće formule G. Kao što prosječan stručnjak područja može razumjeti, ove acilacije se mogu izvesti, na primjer, supstituiranjem s prikladnom karboksilnom kiselinom R;COOH, halogenidom karboksilne kiseline R;COO ili karboksilnim anhidridom R;COOCOR; u gornjem postupku. Kao što je gore navedeno i kao što je nadalje prikazano na shemi 3, taksani opće formule F ili G mogu biti oslobođeni od zaštite na 2'- 1 7-položajima bilo u postupku s dva koraka ili u postupku s jednim korakom Slike 19 do 21 prikazuju kao primjer uklanjanje zaštite s 2'- i 7-položaja.
The compositions may take such forms as solutions, suspensions, or emulsions in aqueous or non-aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or tonicity adjusting agents. 
Pripravci mogu biti u obliku otopina, suspenzija ili emulzija u vodenim ili nevodenim vehikulumima, te mogu sadržavati formulacijska sredstva, poput antioksidansa, pufera, protumikrobnih sredstava i/ili sredstava za podešavanje toničnosti.
The crystal according to claim 9, wherein the crystal has characteristic peaks at diffraction angles of 2θ (±0.5°)=10.1°, 12.6°, 13.1°, 14.0°, 18.6°, 24.2°, 25.2°, 25.7°, 27.2° and 30.5° in its powder X-ray diffraction spectrum, wherein X-ray diffraction spectrum is obtained with Cu Ka as radiation source. 
Kristal prema zahtjevu 1, naznačen time što kristal ima karakteristične vrhove kod kutova difrakcije od 2θ (± 0.5°) = 10.1°, 12.6°, 13.1°, 14.0°, 18.6°, 24.2°, 25.2°, 25.7°, 27.2° i 30.5° u njegovom spektru rendgenske difrakcije praha.
The composition for use according to claim 9, wherein said enemas or paediatric enemas are in disposable formulations. 
Pripravak za uporabu u skladu s patentnim zahtjevom 9, naznačen time, da su rečeni klistiri ili dječji klistiri za jednokratnu primjenu.
The FG 1 can be selected from the group consisting of: acetylene, azide, aldehyde, hydroxylamine, hydrazine, ketone, nitrobenzofurazan (NBD), dansyl, fluorescein, biotin, and Rhodamine. 
(a) vezan na aktivno sredstvo pomoću najmanje jednog veznika, i (b) FG2 je odabran iz skupine koju čine: acetilen, hidroksilamin, azid, aldehid, hidrazin, keton i amin.
The soft chewable veterinary composition of claim 14 wherein the surfactant is polyethylene glycol 12-hydroxystearate. The soft chewable veterinary composition of claim 14 wherein the surfactant is polyethylene glycol 15 12-hydroxystearate. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 14, naznačen time, da tenzid je polietilenglikol-12-hidroksistearat ili polietilenglikol-15-12-hidroksistearat.
The compound according to claim 5 or a pharmacologically acceptable salt thereof, or a solvate or hydrate thereof, wherein in the formula (I), Ar2 is a group selected from the group consisting of A1), A2a), A3), and A7a): 
Spoj u skladu sa patentnim zahtjevom 5 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje u formuli (I), Ar? je grupa odabrana iz grupe koja se sastoji od A1), A2), A3), i A7a):
The reaction mixture was then cooled in an ice-water bath, treated slowly with saturated aqueous ammonium chloride solution (150 ml.) and then treated with IN HC1 (100 ml.). 
Reakcijska smjesa se tada ohladi na kupki led-voda, tretira se lagano sa zasićenom vodenom otopinom natrij-klorida (150 ml) 1 tada se tretira sa IN HCI (100 ml.).
A cement according to any of the preceding claims, wherein the heat-treated clay material constitutes at least 7% w/w and the carbonate material constitutes at least 8% w/w of the cement. 
Cement prema bilo kojem od prethodnih zahtjeva, naznačen time što toplinski obrađeni glineni materijal čini najmanje 7 % m/m i karbonatni materijal čini najmanje 8 % m/m cementa.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahijevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluoromelil-1-melil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, a kao komponentu (B) biksafen.
A process according to claim 1, wherein the solid material is obtained from a process selected from the group consisting of mechanical micronization, milling, jet milling, grinding, rapid precipitation, freeze drying, lyophilisation, and rapid expansion of supercritical solutions. 
Postupak u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, pri čemu je čvrsti materijal dobiven 1z postupka odabranog iz grupe koja se sastoji od mehaničke mikronizacije, mljevenja, mlaznog mljevenja, drobljenja, brzog taloženja, sušenja smrzavanjem, liofilizacije, brze ekspanzije superkritičnih otopina, sušenja raspršivanjem ili njihovih kombinacija, poželjno sušenja raspršivanjem.
is a substituted or unsubstituted aryl, wherein the aryl is selected from phenyl or naphthyl; and R3, R4, R5 and R6 are H; 
je supstituiran ili nesupstituiran aril, pri čemu je aril odabran od fenila ili naftila; i, R4, R5 i R6 su H;
A hybrid fuel supply system for an engine of a vessel, comprising: 
Sustav za slanje hibridnog goriva u brodski motor (100,3), koji se sastoji od:
The aqueous phase was washed with EtOAc, made acidic with conc'd HCl and extracted with CH2Cl2. 
Vodena faza je isprana sa EtOAc, zakiseljena sa konc. HCI i ekstrahirana sa CH,Chk.
reaction of a compound of formula XXVIII, wherein X6 represents a suitable leaving group such, L1 and L2 represent direct bonds, A represents the requisite substituted pyridine-4-yl group as defined in Claim 1, and B is as defined in Claim 1, with a compound of formula XXIX, R1NH2 XXIX wherein R1 is H; 
reakciju spoja s formulom XXVIII, [image] pri čemu X6 predstavlja pogodnu izlaznu skupinu tako da L1 i L2 predstavljaju izravne veze, A predstavlja potrebnu supstituiranu piridin-4-il skupinu kako je definirano u zahtjevu 1, i B je kako je definirano u zahtjevu 1, sa spojem s formulom XXIX, [image] pri čemu R1 je H;
units represent at least one optionally present substitutions for a ring hydrogen atom; or two R10 units can be taken together to form a substituted or unsubstituted C4-C8 cycloalkyl ring, a substituted or unsubstituted C6 or C10 aryl ring, a substituted or unsubstituted C2-C8 heterocyclic ring, or a substituted or unsubstituted C3 to C5 heteroaryl ring, wherein the heterocyclic and heteroaryl rings comprise one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S). 
R'" jedinice predstavljaju barem jednu opcionalno prisutnu supstituciju prstenastog atoma vodika; ili dvije R'" jedinice mogu biti spojene kako bi formirale supstituirani ili nesupstituirani C,-Cg prsten cikloalkila, supstituirani ili nesupstituirani prsten arila C& Or Cig, supstituirani ili nesupstituirani C>-Cg heterociklični prsten, ili supstituirani ili nesupstituirani C3z do Cs5 heteroaril prsten, pri čemu heterociklični 1 heteroarilni prsteni obuhvaćaju jedan ili više hetero atoma neovisno odabranih između kisika (O), dušika (N), ili sumpora (S).
The method for wound healing may comprise exposing the skin to actinic light for a period of about 60 seconds to about 5 minutes per cm2 of an area to be treated. 
Kompozicija za primjenu prema patentnom zahtjevu 8, gdje je navedeno vrijeme tretmana oko 60 sekundi do oko 5 minuta po cm" područja koja treba tretirati.
The liquefied gas treatment method according to claim 1, wherein BOG, which is not supplied as fuel to the main engine and the sub engine among BOG compressed by the compressor, is liquefied by exchanging heat with BOG that is discharged from the cargo tank and transferred to the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što se BOG, koji se komprimira kompresorom (150;13), te prebaci u izmjenjivač topline (21), komprimira prilikom prolaska kroz sve ili dio od više kompresijskih cilindara (14) koje sadrži kompresor.
wherein the suction outlet creates underpressure in the inner region during operation; and wherein the flat surface provides enhanced underpressure and suction effect of the tool towards the surface according to a venturi effect, by water flowing from outside the tool to the inner region without increasing friction. 
Alat prema patentnom zahtjevu 1, naznačen time da ploha za čišćenje ima ravnu površinu unutar oboda, u radu ravna površina osigurava podtlak 1 efekt usisavanja alata prema površini koju treba očistiti po principu Venturijevog efekta.
hydrogen, substituted and unsubstituted alkyl, and 
(7) supstituirani i nesupstituirani alkil, (8) -COR2, i
An implantable medical device according to Claim 13 selected from the group consisting of intravascular devices, catheters, shunts, intubating and tracheotomy tubes, ophthalmic devices, joint prostheses, artificial heart valves and breast implants. 
Implantibilni medicinski uređaj prema zahtjevu 13 naznačen time da je odabran iz skupine koja sadrži intravaskularne uređaje, katetere, šantove, cijevi za intubiranje i traheotomiju, oftalmičke uređaje, proteze za udove, umjetne srčane zaliske i implantate za grudi.
Psychosis may involve delusional or paranoid beliefs. 
Psihoze mogu sadržavati iluzijska ili paranoidna vjerovanja.
The use according to claim 1 or 2, wherein the preparation for regulation of ureolytic flora in the oral cavity, reducing formation of tartar and inhibiting dental caries is manufactured in form of a chewing gum or a tooth paste. 
Primjena u skladu sa patentnim zahtjevima 1 ili 2, naznačeno time da se pripravak za regulaciju ureolitske flore u usnoj šupljini, smanjenje stvaranja zubnog kamenca i dobivanje zubnog karijesa proizvodi u formi guma za žvakanje ili zubne paste.
The bishydrochloride monohydrate salt of the compound of formula (I) or the pharmaceutical composition for use according to claim 5, wherein said condition is selected from mood disorders, and further wherein said mood disorders are selected from depressive disorders or bipolar disorders. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 6, naznačen time što je navedeno stanje odabrano od poremećaja raspoloženja, i pri čemu su navedeni poremećaji raspoloženja dalje odabrani od depresivnih poremećaja ili bipolarnih poremećaja.
A pharmaceutical composition comprising a therapeutically effective amount of the co-crystal according to claim 1 in a physiologically acceptable medium. 
Ko-kristal prema bilo kojem od zahtjeva 1 do 3, naznačen time da tramadol je (-)-tramadol ili (+)-tramadol.
In one embodiment, the hydroxy carboxylic acid or acids are in the form of dimers. In one embodiment, the polyester is a polylactide, a polyglycolide, a polycaprolactone, a copolymer thereof, a terpolymer thereof, or a combination thereof. In one embodiment, the biodegradable thermoplastic polyester is a 50/50, 55/45, 65/35, 75/25, 85/15, 90/10, or 95/5 poly(DL-lactide-co-glycolide) having a carboxy terminal group, or is a 50/50, 55/45, 75/25, 85/15, 90/10, or 95/5 poly(DL-lactide-co-glycolide) without a carboxy terminal group (e.g., capped with a C1 to C10 mono-alcohol), and optionally the polyester without a terminal carboxyl group is extended with a C2 to C12 diol. 
Tekući pripravak prema zahtjevu 4, naznačen time da su hidroksikarboksilna kiselina ili kiseline proizvoljno u obliku dimera; ili pri čemu poliester je polilaktid, poliglikolid, polikaprolakton, njihov kopolimer, njihov terpolimer, ili njihova kombinacija; ili pri čemu biorazgradivi termoplastični poliester je 50/50, 55/45, 65/35, 75/25, 85/15, 90/10, ili 95/5 poli(DL-laktid-ko-glikolid) koji ima karboksi završnu skupinu, ili je 50/50, 55/45, 65/35, 75/25, 85/15, 90/10, ili 95/5 poli(DL- laktid-ko-glikolid) bez karboksi završne skupine, te proizvoljno poliester bez završne karboksilne skupine je produžen sa C2 do C;> diolom; ili pri čemu biorazgradivi termoplastični poliesterski polimer je prisutan u količini 0 tež % do 95 tež %, te proizvoljno biorazgradivi termoplastični poliester ima prosječnu molekulsku težinu od 10,000 do 45,000 Daltona.
the heavy chain Fv fragment of a monovalent Fab forming the antigen-binding domain is linked to one of the polypeptides forming the Fc domain via a CH1 domain; the light chain Fv fragment of the Fab is linked to a CL domain; the heavy chain Fv fragment of the Fab forming the CD3-binding domain is linked to the other polypeptide forming the Fc domain via a CL domain; and the light chain Fv fragment of the Fab is linked to a CH1 domain; 
Fv fragment teškog lanca jednovalentnog Fab koji tvori domenu za vezanje na antigen je vezan na jedan od polipeptida koji tvore Fc domenu preko domene CH1; Fv fragment lakog lanca Fab je vezan na domenu CL; Fv fragment teškog lanca Fab koji tvori domenu za vezanje na CD3 je vezan na drugi polipeptid koji tvori Fc domenu preko domene CL; i Fv fragment lakog lanca Fab je vezan na domenu CH1;
The method as claimed in claim 1, wherein the data carrier is produced with at least two metal sheets arranged parallel above one another, and these two metal sheets are provided with recesses. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time da je nosač podataka proizveden s najmanje dva metalna sloja postavljena paralelno jedan iznad drugoga, te su ta dva metalna sloja predviđena s udubljenjima.
First of all, there is the delay in therapeutic effect of SSRIs. 
Prije svega, terapeutski učinak SSRI ne očituje se odmah.
The soft chewable veterinary composition of claim 14 wherein the surfactant is polyethylene glycol 12-hydroxystearate or polyethylene glycol 15 12-hydroxystearate. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 14, naznačen time, da tenzid je polietilenglikol-12-hidroksistearat ili polietilenglikol-15-12-hidroksistearat.
The term “inactivating agent” refers to a compound that inactivates or crosslinks the active agent, in order to decrease the abuse potential of the transdermal dosage form. 
Pojam "sredstvo za inaktivaciju" odnosi se na spoj koji inaktivira ili umrežuje djelatni sastojak, kako bi smanjio mogućnost zloupotrebe transdermalnog oblika doziranja.
Data transmission device 1 also provides for testing operation of comparing circuits 14a, 14b, particularly the error detecting and storage circuits, simultaneously with telegram transmission to the beacons. 
Naprava za prijenos podataka 1 također omogućuje rad na testiranju uspoređujućih komunikacijskih krugova 14a, 14b, osobito komunikacijskih krugova detektiranja greški i krugova spremanja, istovremeno s prijenosom telegrama prema balizama.
is selected from the group consisting of phenyl(C1-3)alkyl, pyridinyl(C1-3)alkyl, and furanyl(C1-3)alkyl; wherein phenyl, pyridinyl, and furanyl are optionally substituted with one to three R11 substituents independently selected from the group consisting of is C1-3alkoxy; tetrazolyl, C3-6cycloalkylaminocarbonyl; hydroxy(C1-4)alkylaminocarbonyl; C6-10arylaminocarbonyl wherein C6-10aryl is optionally substituted with carboxy or C1-4alkoxycarbonyl; morpholin-4-ylcarbonyl; chloro; fluoro; trifluoromethoxy; methoxycarbonyl; and carboxy; provided that no more than one R11 is C6-10arylaminocarbonyl; 
R! je izabran iz skupine koju čine fenil(C;.g)alkil, piridiniKC,.s)alkil i furani(C,.3)alkil; pri čemu fenil, piridinil i furanil su proizvoljno supstituirani sa jednim do tri R' supstituenta nezavisno izabrana iz skupine koju čine je C1salkoksi; tetrazolil, Cs.gcikloalkilaminokarbonil; hidroksi(C1.4)alkilaminokarbonil; C4_,oarilaminokarbonil pri čemu Cs.qaril je proizvoljno supstituiran sa karboksi ili C,galkoksikarbonil; morfolin-4-ilkarbonil; kloro; fluoro; trifluorometoksi, metoksikarbonil; i karboksi; uz uvjet da ne više od jedan R!! je Csroarilaminokarbonil,; HR P20110694 T1
The process according to claim 7, wherein, during step d), the sodium hydroxide is in equimolar amount with the a-halo acid. 
Postupak prema zahtjevu 7, naznačen time da je tijekom koraka d) natrijev karbonat u ekvimolarnoj količini s a-halogeniziranom kiselinom.
IL-18BP has been suggested as a therapeutic protein in a number of diseases and disorders, such as psoriasis, Crohn's Disease, rheumatoid arthritis, psoriatic arthritis, liver injury, sepsis, atherosclerosis, ischemic heart diseases, allergies, etc., see e.g. WO9909063, WO0107480, WO0162285, WO0185201, WO02060479, WO02096456, WO03080104, WO02092008, WO02101049, WO03013577. 
Za protein IL-18BP se smatra da može pokazivati terapeutske karakteristike u mnogim bolestima i poremećajima poput psorijaze, Crohn-ove bolesti, reumatoidnog artritisa, psorijaznog artritisa, ozljeda jetre, sepse, ateroskleroze, ishemičnih bolesti srca, alergija i si., za ovo vidi WO9909063, WO0107480, WO162285, WO0185201, WO02060479, WO02096456, WO03080104, WO02092008, WO02101049, WO03013577.
In operation S 63, it is determined whether the plurality of candidate intra prediction modes, the number of which is fixed, are used, to predict the intra prediction mode of the current block based on the MPM flag. 
- < dobivanje iz toka bitova, zastavice najvjerojatnijeg načina, koja označava da li je upotrijebljen jedan od kandidata načina unutrašnjeg predviđanja, za određivanje načina unutrašnjeg predviđanja trenutnoga bloka;
The method of claim 42, wherein the cognitive disorders and diseases are selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss. 
Spoj prema patentnom zahtjevu 11, naznačen time što su kognitivni poremećaji 1 bolesti izabrani iz grupe koju čine Alzhajmerova bolest, oblici gubitka pamćenja i gubitak pamćenja ovisan od starenja.
The adapter of claim 1, wherein the first retaining member comprises at least one inwardly extending first projection. 
Adapter (60) prema patentnom zahtjevu 1, naznačen time, da prvi zadržni element sadrži barem jedno prvo izbočenje (78) koje se pruža prema unutra.
The method of any one of clauses 6 - 8, wherein said agent is selected from Olaparib (also known as AZD2281 or KU-0059436), Iniparib (also known as BSI-201 or SAR240550), Veliparib (also known as ABT-888), Rucaparib (also known as PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673, or AZD2461. 
Spoj ili njegova farmaceutski prihvatljiva sol za upotrebu prema bilo kojem od patentnih zahtjeva 1-6, gdje je navedeno dodatno terapeutsko sredstvo Olaparib (također poznat kao AZD2281 ili KU-0059436), Iniparib (također poznat kao BSI-201 ili SAR240550), Veliparib (također poznat kao ABT-888), Rukaparib (također poznat kao PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMNG673, ili AZD2461.
The compound of embodiment 43, wherein the human papilloma virus is selected from the group consisting human papilloma virus type 11, type 16 and type 18. 
(b) ljudski papilomavirus je odabran iz skupine koja se sastoji od ljudskog papilomavirusa tipa 11, tipa 16 i tipa 15.
Cracking furnace according to any one of the claims 7-14, wherein at least part of the cracking coils, are arranged in a arrangement allowing parallel flow of the feed through each of the coils, during use. 
Peć za cijepanje prema bilo kojem zahtjevu 7 do 13, naznačena time, da su barem neke od spirala za cijepanje raspoređene u poretku koji dozvoljava paralelni protok opskrbnog materijala kroz svaku spiralu, prilikom uporabe.
The method of anyone of the preceding claims, wherein the sorbent particles comprise particles selected from the group consisting of alumina particles, silica particles, and combinations thereof. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što čestice sorbensa sadrže čestice koje se bira iz skupine koju čine čestice aluminijevog oksida, čestice silicijevog dioksida i njihove kombinacije.
a second separation step S3' which consists in the separation of the fraction F3 in a column C3' into the fraction A at the top of column C3' and into fraction B at the bottom of column C3'. 
drugi korak odvajanja S3' koji se sastoji u odvajanju frakcije F3 u koloni C3' u frakciju A na vrhu kolone C3' i u frakciju B na dnu kolone C3'.
Figure 1: Representation of the TCR-CD3 complex. 
Datum objave europske prijave patenta: